Navigation Links
SGX Pharmaceuticals BCR-ABL Program to be Presented at the American Society of Hematology 49th Annual Meeting and Exposition
Date:12/6/2007

SAN DIEGO, Dec. 6 /PRNewswire-FirstCall/ -- SGX Pharmaceuticals, Inc. (Nasdaq: SGXP) announced today details of two presentations from the Company's BCR-ABL program for the treatment of chronic myelogenous leukemia (CML) at the upcoming American Society of Hematology's 49th Annual Meeting and Exposition. The conference is being held December 8th - 11th, 2007 in Atlanta, Georgia.

The schedule for these sessions, together with the abstract information, is listed below:

Date: Saturday, December 8, 2007 from 5:30pm - 7:30pm EST

Session Type: Poster Session, Board #172-I

Abstract: #1018

Title: "Co-Crystal Structures of 7-Azaindole Inhibitors of

Wild-Type and T315I Imatinib-Resistant Mutant Forms of the

BCR-ABL Tyrosine Kinase."

Description: This poster presentation describes how the SGX393 chemical

family of BCR-ABL inhibitors discovered by SGX can provide

potent, selective inhibition of both wild type and major

drug resistant mutant forms of BCR-ABL including T315I.

The poster discusses the impact of seven BCR-ABL mutations

on the co-crystal structures of the SGX393 family of

inhibitors, including the challenging T315I, G250E and

F317L mutations. SGX393 represents an illustrative example

of how the integrated SGX FAST fragment-based,

structure-guided drug discovery platform can be used to

generate high-quality, low molecular weight inhibitors of

oncology targets.

Date: Monday, December 10, 2007 from 1:30pm - 3:00pm EST

Session Type: Oral Session

Abstract: #535

Title: "SGX70393 Inhibits BCR-ABL & T315I In Vitro and In Vivo

and Completely Suppresses Resistance When Combined with

Nilotinib or Dasatinib."

Description: An oral presentation, coauthored with collaborators at the

Oregon Health & Science University Cancer Institute,

describes a proof of principle study demonstrating the

potential of combination targeted therapy for CML. SGX393

(also known as SGX70393) is a potent, selective

orally-bioavailable inhibitor of both wild type and major

drug resistant mutant forms of BCR-ABL, including the most

challenging T315I mutation.

"These two ASH presentations explain how SGX is using its

drug discovery platform to discover and optimize potent,

selective and orally-bioavailable inhibitors of important

oncology drug discovery targets," said Stephen Burley,

Chief Scientific Officer of SGX Pharmaceuticals.

"Moreover, the results obtained with our collaborators at

the Oregon Health & Science University Cancer Institute

demonstrate the potential of targeted combination therapy

for CML. A number of influential thought leaders believe

that effective management of newly-diagnosed CML will

depend on long-term treatment with multiple agents

possessing non-overlapping resistance profiles."

About the SGX BCR-ABL Program

SGX393 is an internally developed, orally-bioavailable, small molecule inhibitor of the abnormal BCR-ABL tyrosine kinase, which results from a characteristic chromosome abnormality (also known as the Philadelphia chromosome) that causes chronic myelogenous leukemia or CML, a cancer of the bone marrow. SGX393 has shown both potent in vitro blockade of the activity of BCR-ABL and in vivo activity against human leukemic cells that depend on BCR-ABL for their uncontrolled growth and proliferation. In addition, SGX393 has shown potent activity against a broad spectrum of mutant forms of BCR-ABL that render this cancer target resistant to imatinib (Gleevec (R)), the current standard of care for CML. One of the key drug resistant forms of BCR-ABL inhibited by SGX393 is the T315I mutation, which is also resistant to the two second-generation BCR-ABL inhibitors, nilotinib (Tasigna (R)) and dasatinib (Sprycel (R)). In addition, SGX is engaged in a strategic collaboration with Novartis that aims to discover and develop next generation BCR-ABL inhibitors for treatment of newly-diagnosed CML patients.

About SGX Pharmaceuticals

SGX Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of innovative cancer therapeutics. The SGX oncology pipeline includes drug candidates from its FAST(TM) drug discovery platform, such as next generation BCR-ABL inhibitors being developed by SGX and in partnership with Novartis and cMET tyrosine kinase inhibitors, including SGX523, and JAK2 inhibitors. More information on the pipeline and drug discovery platform can be found at http://www.sgxpharma.com and in the Company's various filings with the Securities and Exchange Commission.

Forward-looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements include, but are not limited to, research and development programs, the potential of SGX's BCR-ABL inhibitors as treatments for chronic myelogenous leukemia and the ability to discover, develop and commercialize cancer therapeutics. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug discovery, development and commercialization. The results of early preclinical studies or clinical trials may not be predictive of future results, and the Company cannot provide any assurances that any of its compounds or development candidates will have favorable results in preclinical studies or future clinical trials. For a discussion of these and other factors, please refer to the risk factors described in the Company's annual report on Form 10-K for the year ended December 31, 2006, the Company's quarterly report on Form 10-Q for the three and nine months ended September 30, 2007, as well as other filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and SGX undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.


'/>"/>
SOURCE SGX Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
7. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
9. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
10. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
11. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... , ... First Choice Emergency Room , the largest network of independent ... Director of its new Mesquite-Samuell Farm facility. , “We are pleased to announce ... Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van ... Wellness at Work award to iHire in recognition of their exemplary accomplishments in worksite ... 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum ...
(Date:6/24/2016)... ... 2016 , ... Those who have experienced traumatic events may suffer from a ... such as drug or alcohol abuse, as a coping mechanism. To avoid this pain ... following a traumatic event. , Trauma sufferers tend to feel a range of emotions, ...
(Date:6/24/2016)... Dallas, Texas (PRWEB) , ... June 24, 2016 ... ... 12th International Conference and Scientific Sessions in Dallas that it will receive two ... Announcement of the grants came as PHA marked its 25th anniversary by recognizing ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited ... To Recovery® program to drive cancer patients to and from their cancer treatments. ... highest quality of life and ongoing independence. Getting to and from medical treatments ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016 Research and Markets ... for Companion Diagnostic Tests" report to their offering. ... Companion Diagnostics The World Market for Companion ... medicine diagnostics. Market analysis in the report includes the following: ... (In Vitro Diagnostic Kits) by Region (N. America, EU, ROW), ...
(Date:6/24/2016)... KNOXVILLE, Tenn. , June 24, 2016 /PRNewswire/ ... market providing less invasive and more durable cerebrospinal ... million in funding.  The Series-A funding is led ... the Lighthouse Fund, and other private investors.  Arkis, ... less-invasive neurosurgical instrumentation and the market release of ...
(Date:6/23/2016)... Research and Markets has announced the addition ... Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, Binder, ... Forecast to 2021" report to their offering. ... excipients market is projected to reach USD 8.1 Billion ... forecast period 2016 to 2021. The ...
Breaking Medicine Technology: